Please login to the form below
Keytruda
This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
While patients whose tumours express PD-L1 can receive immunotherapies like Merck/MSD’s Keytruda (pembrolizumab), advanced TNBC remains a very difficult cancer to treat.
Latest news
-
Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
Elsewhere in its Q2 results, Merck saw sales growth for its blockbuster immunotherapy Keytruda, which grew by 23% to $4.2bn, reflecting continued demand in the major non-small cell lung
-
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process. ... The Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process for the treatment of certain endometrial cancer patients.
-
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
Merck &Co – known as MSD outside the US and Canada – has highlighted new data for its blockbuster immunotherapy Keytruda used before and after surgery in high-risk, early-stage triple negative ... Now, Merck has additional data to make its case for
-
Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer
The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data. ... Among these, Keytruda achieved an overall response rate of just over 13% (19 patients), with a complete response rate of 1.4%.
-
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
Instead of targeting a specific genetic defect, Keytruda targets tumours that have a high degree of genetic instability. ... As Vitrakvi and Rozlytrek lead with their TA indications, the challenges faced by these therapies are wholly different to Keytruda
More from news
Approximately 169 fully matching, plus 278 partially matching documents found.
Latest Intelligence
-
Putting commercial intelligence at the heart of strategy
Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting
-
20 for 2020 – Five pharma companies to watch
Opdivo is being squeezed out of the market by Merck &Co/ MSD’s Keytruda (pembrolizumab), which dominates the lucrative first-line NSCLC market and is cutting into BMS’ share of the ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor
-
25 Women Leaders in UK Healthcare
its role in developing immuno-oncology blockbuster Keytruda. ... The coming Keytruda windfall will also allow the charity to set up a stand-alone venture capital division, with which it could seed funding and help promote research in key areas.
-
2019: CRISPR and therapeutic gene editing comes of age
The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the
-
Immuno-oncology in 2019: the rapid evolution continues
PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.
More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Merck’s CEO Kenneth Frazier to retire after ten years in the role
Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types. ... Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations,
-
BMS appoints new commercial leader, Davies joins Eisai and more
The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
OncoSec’s intratumoral IL-12 EP platform not only enhances anti–PD-(L) 1 activity (currently treating anti-PD-1–refractory melanoma patients with pembrolizumab [Keytruda] plus its investigational TAVO in
-
Mastering the precision medicine opportunity
Last year the FDA made a pioneering move in this space and approved Keytruda for use in adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or
-
18 SWITCHED ONcology: The Big Communication
Here’s a look at Keytruda, the drug Jimmy Carter says made his tumors vanish.
-
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
However, hidden in the pipeline was the ‘miracle’ immuno-oncology drug Keytruda.
-
A stumble, but not a fall – what’s next for Opdivo?
Impressively, Opdivo consistently outperformed Merck &Co.'s ($MRK) Keytruda (pembrolizumab), racking up $1.58 billion in sales during the first half of 2016 compared to $563 million earned by its main ... Rubbing salt into BMS’s wounds, Merck's
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- bluebird bio’s beti-cel accepted for priority review by FDA
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
- Onyx Health Announces Two Top Appointments
- Omicron prompts global action
- Novo Nordisk growth takes a hit with China deal
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- AstraZeneca officially opens new R&D facility in UK
- Biogen hands out $120m upfront for Remedy stroke drug
- China backs use of Roche’s Actemra for coronavirus
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
